Exam 2004 (A) - Name UFID PHA 5515 Exam Form A Total 119...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Name: _____________________ UFID: ________________________ PHA 5515 April 21, 2004 Exam Form A Total: 119 points Read each question carefully before answering. Answer only the question that is written on the page; don’t add any of your own parts to it. Remember the Academic Dishonesty Policy; keep your eyes on your own paper. Please turn in the test and answer sheets when you have finished. Good Luck! Pages 2-11
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Marijuana is being considered as an antiemtic and appetite stimulant agent for use in cancer and AIDS patients. However, this drug has significant immunosuppressant effects that can be detrimental to both patient populations. It is known that the active ingredient in marijuana is delta-9-THC (D9) which binds to two subtypes of cannabinoid receptors, CB1 and CB2. You compare the potencies and efficacies of D9 to those of a number of other experimental cannabinoids (CP55, WIN, HU, AEA and SR14) that also increase appetite (Figure 1) but may suppress immune function (Figure 2). You also measure and compare the efficacies and potencies of these six drugs to displace the specific binding of 3 H-D9 from homogenized brain samples. About two thirds of the receptors (Subtype CB1) occupied by 3 H-D9 only bind CP55 while the other third of the receptors (Subtype CB2) only bind SR14. Which of the following conclusions would be valid after examining the resulting competition curves shown in Figure 3? 1. SR14 would be able to compete for at least a portion of specific binding if a competi- tion curve were performed using 3 H- CP55 as the radiolabeled drug. 2. AEA would be able to compete for at least a portion of specific binding if a competi- tion curve were performed using 3 H-HU as the radiolabeled drug. 3. Both D9 and HU can bind to both Subtypes CB1 and CB2 but the IC 50 values for the two subtypes are more alike for D9 than they are for HU. 4. SR 14 can not bind specifically to any CB receptors at nanomolar concentrations. 5. WiN clearly has a lower affinity for the Subtype CB1 site compared to its affinity for the Subtype CB2 site. 6. D9 clearly has a lower affinity for the Subtype CB1 site compared to WIN’s affinity for the Subtype CB1 site. 7. You would suspect that 66% of the D9 receptors (Subtype CB1) are involved in mediating the appetite stimulating effects. 8. You would suspect that 34% of the D9 receptors (Subtype CB2) are involved in mediating the immunosuppressant effects of these agents. 9. SR14 is an antagonist at Subtype CB2 receptors. 10. HU is a partial agonist at Subtype CB1 receptors. 11. AEA is a partial agonist at Subtype CB2 receptors. 12. The best drug to give an AIDS patient to increase appetite would be CP55 if it had no other serious side effects. 2
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}

Page1 / 13

Exam 2004 (A) - Name UFID PHA 5515 Exam Form A Total 119...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online